Clinical Trial Update: Safety Study of MGAH22 in HER2-positive Carcinomas [Phase 1]

View source ↗

Summary

This clinical trial update reports a Phase 1 safety study of MGAH22 in HER2-positive carcinomas, which has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Gastric Cancer

Drugs mentioned

• MGAH22

Snippet

Sponsor: MacroGenics | Conditions: Breast Cancer, Gastric Cancer | Phase 1 | Status: COMPLETED